Angiogenesis inhibitors in the treatment of lung cancer

Sophie Sun, Joan H. Schiller

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Despite improvements in cytotoxic chemotherapy and combined modality therapies for lung cancer, the prognosis for patients remains poor, and the majority of patients die from the disease. Angiogenesis, i.e. the formation of new blood vessels, is important for tumor growth, invasion and metastasis and represents a rational target in the development of more effective treatments. The vascular endothelial growth factor (VEGF) signaling pathway plays a crucial role in the angiogenic process and consequently, inhibitors of this system are currently under development. The most studied anti-angiogenic agents include anti-VEGF monoclonal antibodies and VEGF receptor tyrosine kinase inhibitors. Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)93-104
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume62
Issue number2
DOIs
StatePublished - May 2007

Fingerprint

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Lung Neoplasms
Combined Modality Therapy
Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Blood Vessels
Therapeutics
Monoclonal Antibodies
Clinical Trials
Neoplasm Metastasis
Drug Therapy
Growth
Neoplasms

Keywords

  • Angiogenesis inhibitors
  • Lung cancer
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Angiogenesis inhibitors in the treatment of lung cancer. / Sun, Sophie; Schiller, Joan H.

In: Critical Reviews in Oncology/Hematology, Vol. 62, No. 2, 05.2007, p. 93-104.

Research output: Contribution to journalArticle

Sun, Sophie ; Schiller, Joan H. / Angiogenesis inhibitors in the treatment of lung cancer. In: Critical Reviews in Oncology/Hematology. 2007 ; Vol. 62, No. 2. pp. 93-104.
@article{c0f6bfbbf9374c7db7efa4bdc6d75d12,
title = "Angiogenesis inhibitors in the treatment of lung cancer",
abstract = "Despite improvements in cytotoxic chemotherapy and combined modality therapies for lung cancer, the prognosis for patients remains poor, and the majority of patients die from the disease. Angiogenesis, i.e. the formation of new blood vessels, is important for tumor growth, invasion and metastasis and represents a rational target in the development of more effective treatments. The vascular endothelial growth factor (VEGF) signaling pathway plays a crucial role in the angiogenic process and consequently, inhibitors of this system are currently under development. The most studied anti-angiogenic agents include anti-VEGF monoclonal antibodies and VEGF receptor tyrosine kinase inhibitors. Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer.",
keywords = "Angiogenesis inhibitors, Lung cancer, Tyrosine kinase inhibitors, Vascular endothelial growth factor",
author = "Sophie Sun and Schiller, {Joan H.}",
year = "2007",
month = "5",
doi = "10.1016/j.critrevonc.2007.01.002",
language = "English (US)",
volume = "62",
pages = "93--104",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Angiogenesis inhibitors in the treatment of lung cancer

AU - Sun, Sophie

AU - Schiller, Joan H.

PY - 2007/5

Y1 - 2007/5

N2 - Despite improvements in cytotoxic chemotherapy and combined modality therapies for lung cancer, the prognosis for patients remains poor, and the majority of patients die from the disease. Angiogenesis, i.e. the formation of new blood vessels, is important for tumor growth, invasion and metastasis and represents a rational target in the development of more effective treatments. The vascular endothelial growth factor (VEGF) signaling pathway plays a crucial role in the angiogenic process and consequently, inhibitors of this system are currently under development. The most studied anti-angiogenic agents include anti-VEGF monoclonal antibodies and VEGF receptor tyrosine kinase inhibitors. Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer.

AB - Despite improvements in cytotoxic chemotherapy and combined modality therapies for lung cancer, the prognosis for patients remains poor, and the majority of patients die from the disease. Angiogenesis, i.e. the formation of new blood vessels, is important for tumor growth, invasion and metastasis and represents a rational target in the development of more effective treatments. The vascular endothelial growth factor (VEGF) signaling pathway plays a crucial role in the angiogenic process and consequently, inhibitors of this system are currently under development. The most studied anti-angiogenic agents include anti-VEGF monoclonal antibodies and VEGF receptor tyrosine kinase inhibitors. Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer.

KW - Angiogenesis inhibitors

KW - Lung cancer

KW - Tyrosine kinase inhibitors

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=34147092163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147092163&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2007.01.002

DO - 10.1016/j.critrevonc.2007.01.002

M3 - Article

C2 - 17306557

AN - SCOPUS:34147092163

VL - 62

SP - 93

EP - 104

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -